| Literature DB >> 33603970 |
Yeon Hee Lee1,2, Hyeon-Min Cha1,3, Jun Yeon Hwang1, So Yeong Park1,2, Avinash G Vishakantegowda1,2, Ali Imran1, Joo-Youn Lee1, Yoon-Sun Yi4, Sangmi Jun4, Ga Hyeon Kim5,6, Hyo Jin Kang6, Sang J Chung5,6, Meehyein Kim1,3, Hyejin Kim1, Soo Bong Han1,2.
Abstract
As the spread of infections caused by hepatitis B virus (HBV) threatens public health worldwide, investigations from multiple perspectives and of various mechanisms of action are urgently required to increase the HBV cure rate. Targeting the encapsidation of the nuclear capsid protein (core protein, HBc) has emerged as an attractive strategy for inhibiting the viral assembly process; however, a drug targeting this mechanism has not yet been approved. We synthesized novel sulfamoylbenzamides (SBAs) as capsid assembly modulators of HBV and found that the effects and safety profiles of compounds 3 and 8 have potential therapeutic applicability against HBV. The formation of tubular particles was time-dependent in the presence of 3, indicating a new mode of protein assembly by SBA compounds. Our findings provide a new entity for developing safe and efficient treatments for HBV infection.Entities:
Year: 2021 PMID： 33603970 PMCID： PMC7883466 DOI： 10.1021/acsmedchemlett.0c00606
Source DB: PubMed Journal: ACS Med Chem Lett ISSN： 1948-5875 Impact factor: 4.345